Genmab A+s

Biontech Se

Universitãt Stuttgart

Biontech Rna Pharmaceuticals Gmbh

Tron—translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-universitat Mainz Ggmbh

Sanofi

Tron-translationale Onkologie an Der Universitatsmedizin Der Johannes Gutenberg-universitat Mainz

Biotech Rna Pharmaceuticals Gmbh

Tron—translationale Onkologie an Der Universitátsmedizin Der Johannes Gutenberg—universität Mainz Gemeinnützige Gmbh

Tron Translationale Onkologie an Der Universitaetsmedizin Der Johannes Gutenberg-universitaet Mainz Ggmbh

Friederike Gieseke

Ugur Sahin

Paul Parren

David Satijn

Isil Altintas

Rik Rademaker

Sebastian Kreiter

Alexander Muik

Roland Kontermann

Klaus Pfizenmaier

Dafne Müller

Christian Grunwitz

Ronald Backer

Edward Norbert Van Den Brink

Janine Schuurman

Aran Frank Labrijn

Mustafa Diken

Joost J Neijssen

Dennis Verzijl

Esther Cornelia Wilhelmina Breij

Richard Hibbert

Sina Fellermeier-kopf

Bart-Jan De Kreuk

Lars Guelen

Sina Fellermaier

Timothy R Wagenaar

Dmitri G Wiederschain

Christian Hotz

Karsten Beckmann

Claudia Paulmann

Ivan Kuzmanov

Patricia Garrido Castro

Sina Fellermeier

Jordan Blum

Dafne Muller

The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.

Binding agents that bind OX40 (CD134) and method of use thereof to treat disease

Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

Multispecific antibodies against CD40 and CD137

The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.

Monoclonal antibodies directed against programmed death-1 protein and their use in medicine

This disclosure relates to the field of therapeutic RNAs for treatment of solid tumor cancers.

Therapeutic RNA

Nucleic acid molecules encoding binding agents to CD40 and 4-1BB (CD137)

The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.

Binding agents binding to PD-L1 and CD137 and use thereof

Methods of producing multispecific antibodies against CD40 and CD137

Agonistic tumor necrosis factor (TNF) receptor binding agents

The present invention relates to cytokine fusion proteins and to nucleic acid molecules encoding such cytokine fusion proteins. The present invention further relates to cells, non-human organisms. pharmaceutical compositions and kits comprising the cytokine fusion proteins or the nucleic acid molecules encoding them, as well as to their use as medicaments.

Nucleic acid molecules encoding cytokine fusion proteins comprising tumor necrosis factor (TNF) superfamily ligands

The present invention relates to cytokine fusion proteins and to nucleic acid molecules encoding such cytokine fusion proteins. The present invention further relates to cells, non-human organisms, pharmaceutical compositions and kits comprising the cytokine fusion proteins or the nucleic acid molecules encoding them, as well as to their use as medicaments.

RNA molecules encoding cytokine fusion proteins and methods of use thereof

Methods of inducing T cell activation by administering an antibody comprising CD40 and 4-1BB (CD137) binding domains

Growing community of inventors

Mainz, Germany

Friederike Gieseke